The Antitumor Assessment Core provides support for early discovery of effective antitumor agents and therapeutics. The Core provides resources, professional and technical expertise and advisory services related to the evaluation of agents with potential therapeutic activity, and works closely with investigators to establish in vivo mouse models, including Patient Derived Xenograft (PDX) models, for the design and execution of pharmacokinetic, toxicity and in vivo efficacy studies. The Core also determines the best formulation, administration route, and treatment schedule for each new compound, either alone or in combination with other agents. As such, the Core provides a major vehicle to facilitate pre-clinical studies, including GLP-compliant safety toxicology studies in support of IND applications, and is a major contributor to the translational mission of the Center. The Core helps investigators to design, plan, and execute their in vivo experiments, prepare animal protocols and grant applications involving animal studies, and analyze and summarize data for publication and for IND reporting. Importantly, the Core acts as a central coordinator for studies involving support from several Core facilities (including Animal Imaging, Comparative Medicine and Pathology, Tissue Procurement Service, Organic Synthesis, Integrated Genomics, Radiochemistry and Molecular Imaging Probes, and Molecular Cytology) so that studies are carried out properly and in a time- and cost-efficient manner.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Sloan-Kettering Institute for Cancer Research
New York
United States
Zip Code
Isharwal, Sumit; Huang, Hongying; Nanjangud, Gouri et al. (2018) Intratumoral heterogeneity of ERBB2 amplification and HER2 expression in micropapillary urothelial carcinoma. Hum Pathol 77:63-69
Ghuman, Marcus; Hwang, Sinchun; Antonescu, Cristina R et al. (2018) Plexiform fibrohistiocytic tumor: imaging features and clinical findings. Skeletal Radiol :
Kim, Jisun; Geyer, Felipe C; Martelotto, Luciano G et al. (2018) MYBL1 rearrangements and MYB amplification in breast adenoid cystic carcinomas lacking the MYB-NFIB fusion gene. J Pathol 244:143-150
Neuschmelting, Volker; Kim, Kwanghee; Malekzadeh-Najafabadi, Jaber et al. (2018) WST11 Vascular Targeted Photodynamic Therapy Effect Monitoring by Multispectral Optoacoustic Tomography (MSOT) in Mice. Theranostics 8:723-734
Hyman, David M; Piha-Paul, Sarina A; Won, Helen et al. (2018) HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature 554:189-194
Turesson, Ingemar; Bjorkholm, Magnus; Blimark, Cecilie Hveding et al. (2018) Rapidly changing myeloma epidemiology in the general population: Increased incidence, older patients, and longer survival. Eur J Haematol :
Moo, Tracy-Ann; Edelweiss, Marcia; Hajiyeva, Sabina et al. (2018) Is Low-Volume Disease in the Sentinel Node After Neoadjuvant Chemotherapy an Indication for Axillary Dissection? Ann Surg Oncol 25:1488-1494
Kinsley, Karen; Pritchett, Wendy (2018) Liposomal Irinotecan: Nursing Considerations in an Outpatient Cancer Center Clin J Oncol Nurs 22:221-224
Vargas, Hebert Alberto; Kramer, Gem M; Scott, Andrew M et al. (2018) Reproducibility and Repeatability of Semiquantitative 18F-Fluorodihydrotestosterone Uptake Metrics in Castration-Resistant Prostate Cancer Metastases: A Prospective Multicenter Study. J Nucl Med 59:1516-1523
Ho, A L (2018) Developing androgen receptor targeting for salivary gland cancers. Ann Oncol 29:792-794

Showing the most recent 10 out of 8799 publications